NeuroSense Advances ALS Treatment with PrimeC Through Strategic Partnership
NeuroSense Therapeutics (NRSN) has announced a significant step forward in the fight against amyotrophic lateral sclerosis (ALS) by entering into a binding term sheet with a leading global pharmaceutical company. This partnership aims to advance the development and commercialization of PrimeC, NeuroSense's proprietary treatment for ALS, in certain key territories. Under the terms of the agreement, NeuroSense will retain full rights to PrimeC in other key territories.
The binding term sheet outlines several substantial financial terms provided by the pharmaceutical company, including:
- A substantial upfront payment upon signing a definitive agreement;
- Funding for the Phase 3 clinical trial;
- Regulatory and net sales milestone payments; and
- A tiered royalty structure reaching double-digit percentage on annual net sales.
This agreement is subject to the finalization of a definitive agreement, which is anticipated in the first quarter of 2025. The pharmaceutical company would gain an exclusive license to distribute, market, promote, sell, and develop PrimeC for ALS in certain key markets, along with non-exclusive rights for research and manufacturing for PrimeC for ALS, all subject to the terms and conditions outlined in the definitive agreement.
This strategic partnership marks a pivotal moment for NeuroSense Therapeutics, as it not only boosts the company's financial position but also accelerates the development of a potentially life-changing treatment for ALS patients worldwide.